Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORT · Real-Time Price · USD
88.43
-1.89 (-2.09%)
At close: Oct 8, 2025, 4:00 PM EDT
88.00
-0.43 (-0.49%)
After-hours: Oct 8, 2025, 5:26 PM EDT
Corcept Therapeutics Revenue
Corcept Therapeutics had revenue of $194.43M in the quarter ending June 30, 2025, with 18.70% growth. This brings the company's revenue in the last twelve months to $716.08M, up 25.71% year-over-year. In the year 2024, Corcept Therapeutics had annual revenue of $675.04M with 39.94% growth.
Revenue (ttm)
$716.08M
Revenue Growth
+25.71%
P/S Ratio
13.09
Revenue / Employee
$1,432,160
Employees
500
Market Cap
9.32B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 675.04M | 192.67M | 39.94% |
Dec 31, 2023 | 482.38M | 80.52M | 20.04% |
Dec 31, 2022 | 401.86M | 35.88M | 9.80% |
Dec 31, 2021 | 365.98M | 12.10M | 3.42% |
Dec 31, 2020 | 353.87M | 47.39M | 15.46% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
CORT News
- 7 days ago - Curant Rare Announces Pharmacy Partnership with Corcept Therapeutics - Business Wire
- 9 days ago - 4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals - Benzinga
- 12 days ago - Corcept Primed For An Upside EPS Surprise - Seeking Alpha
- 16 days ago - Corcept to Present New Late-Breaking Data From Pivotal ROSELLA Trial of Relacorilant in Platinum-Resistant Ovarian Cancer at ESMO 2025 - Business Wire
- 23 days ago - 11 fast-growing small-cap stocks that could get a boost from the Fed's next move - Market Watch
- 4 weeks ago - FDA Files Corcept's New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer - Business Wire
- 2 months ago - Corcept's Q2 Demand Grows 60%, Penetrating Large Type 2 Diabetes Market Early - Seeking Alpha
- 2 months ago - Corcept Therapeutics Incorporated (CORT) Q2 2025 Earnings Call Transcript - Seeking Alpha